References

clinmed

Клиническая медицина

Clinical Medicine (Russian Journal)

0023-21492412-1339

ООО «Медицинское информационное агентство»

10.30629/0023-2149-2020-98-11-12-759-765

clinmed-158

Research Article

ОБЗОРЫ И ЛЕКЦИИ

REVIEWS AND LECTURES

Эктопические жировые отложения как фактор сердечно-сосудистого риска у пациентов с неалкогольной жировой болезнью печени

Ectopic fat depots as a factor of cardiovascular risk in patients with nonalcoholic fatty liver disease

https://orcid.org/0000-0002-3306-0312

Стаценко

М. Е.

Statsenko

M. E.

400131, Волгоград

400131, Volgograd

https://orcid.org/0000-0002-8844-2465

Туркина

С. В.

Turkina

S. V.

Туркина Светлана Владимировна — доктор медицинских наук, профессор кафедры внутренних болезней

400131, Волгоград

Svetlana V. Turkina — MD, PhD, DSc, Professor of the Department of Internal Medicine

400131, Volgograd

turkina.vlg@gmail.com

https://orcid.org/0000-0002-3046-7264

Тыщенко

И. А.

Tyshchenko

I. A.

400131, Волгоград

400131, Volgograd

https://orcid.org/0000-0001-7367-7248

Горбачева

Е. Е.

Gorbacheva

E. E.

400131, Волгоград

400131, Volgograd

ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава РоссииРоссияVolgograd State Medical University of the Ministry of Healthcare of the Russian FederationRussian Federation

2020

17042021

9811-12759765

2021

Стаценко М.Е., Туркина С.В., Тыщенко И.А., Горбачева Е.Е.

Statsenko M.E., Turkina S.V., Tyshchenko I.A., Gorbacheva E.E.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.clinmedjournal.com/jour/article/view/158

Обзор посвящен оценке влияния эктопических жировых отложений на развитие сердечно-сосудистых заболеваний (ССЗ) у пациентов с неалкогольной жировой болезнью печени (НАЖБП). На сегодняшний день НАЖБП — наиболее распространенное хроническое заболевание печени в большинстве стран мира. Ряд исследований подтвердил важную роль НАЖБП в формировании и прогрессировании ССЗ, что проявляется повышением рисков сердечно-сосудистых событий у пациентов с НАЖБП по Фрамингемской шкале. На сегодняшний день все больше подтверждений находит мнение, что НАЖБП должна быть признана в качестве независимого фактора риска развития ССЗ, помимо других метаболических нарушений. Одним из возможных механизмов взаимосвязи НАЖБП и ССЗ является паракринная активность висцеральной жировой ткани; обсуждается возможность наличия локальных эффектов различных эктопических отложений висцерального жира. Не вызывает сомнения тот факт, что в формировании гепатокардиального континуума важную роль играет эпикардиальная жировая ткань. Появляется все больше работ, оценивающих влияние и других эктопических депо на развитие ССЗ у пациентов с НАЖБП. В статье приведен анализ публикаций, посвященных вопросам взаимосвязи жировых эктопических депо и рисков ССЗ у пациентов с НАЖБП. Поиск статей осуществлялся в базах данных MedLine и PubMed на английском и русском языках. В обзор вошли статьи, опубликованные с 2000 по 2020 г.

The review represents evaluation of the ectopic fatty depots effect on the development of cardiovascular diseases (CVD) in patients with nonalcoholic fatty liver disease (NAFLD). Nowadays, NAFLD is the most common cause of chronic liver disease in most countries of the world. A number of studies have confirmed the important role of NAFLD in the formation and progression of CVD, which is manifested by an increased risk of cardiovascular events in patients with NAFLD according to Framingham Risk Score. The statement that NAFLD should be recognized as an independent risk factor for CVD, in addition to other metabolic disorders, is often confirmed. One of the possible mechanisms of interrelation between NAFLD and CVD is the paracrine activity of visceral adipose tissue; the possibility of local effects of various ectopic depots of visceral fat is being discussed. There is no doubt that epicardial adipose tissue plays an important role in the formation of the hepato-cardiac continuum. Тhere are more and more studies evaluating the effect of other ectopic depots on the development of CVD in patients with NAFLD. The article provides an analysis of publications devoted to the interrelation between fatty ectopic depots and CVD risks in patients with NAFLD. MedLine and PubMed databases in English and Russian languages were used for the search. The review includes articles published from 2000 to 2020.

обзорнеалкогольная жировая болезнь печениэпикардиальная жировая тканьпериваскулярная жировая тканьжировые отложения в почкахриск сердечно-сосудистых осложнений

reviewnon-alcoholic fatty liver diseaseepicardial adipose tissueperivascular adipose tissuefatty depots in the kidneysrisk of cardiovascular complications

References1

Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.

Younossi Z., Anstee Q.M., Marietti M. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018;15:11–20.

Ивашкин В.Т., Драпкина О.М., Маев И.В., Трухманов А.С., Блинов Д.В., Пальгова Л.К. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;6:31–41.

Ivashkin V.T., Drapkina O.M. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(6):31–41 (in Russian)

Velarde-Ruiz Velasco J.A., García-Jiménez E.S., García-Zerme-nõ K.R. et al. Complicaciones extrahepáticas de la enfermedad por hígado graso no alcohólico: impacto más allá del hígado. Revista de Gastroenterología de México. 2019;84:472–481.

Motamed N., Rabiee B., Poustchi H. et al. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases. Clin. Res. Hepatol. Gastroenterol. 2017;41:31–38.

Wu S., Wu F., Ding Y. et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. SciRep. 2016;16:33386.

Uchasova E.G., Gruzdeva O.V., Dyleva Yu.A., Akbasheva O.E. Epicardial adipose tissue: pathophysiology and role in the development of cardiovascular diseases. Bulletin of Siberian Medicine. 2018;17(4):254–263 (in Russian)

Şengül C., Özveren O. Epicardialadipose tissue: a review of physiology, pathophysiology and clinical applications. Anadolu Kardiyol. Derg. 2013;13(3):261–265. DOI: 0.5152/akd.2013.075.

Осихов И.А., Беспалова И.Д., Бычков В.А., Рязанцева Н.В., Калюжин В.В., Афанасьева С.Д. и др. Нарушения межклеточных взаимодействий в патогенезе воспаления жировой ткани при метаболическом синдроме. Бюллетень сибирской медицины. 2013;12(6):144–153.

Osikhov I.A., Bespalova I.D., Bychkov V.A., Ryazantseva N.V., Kalyuzhin V.V., Afanasyeva D.S. et al. Disorder of intracellular correlations in pathogenesis of fatty tissue inflammation in metabolic syndrome. Bulletin of Siberian Medicine. 2013;12(6):144–153 (in Russian)

Bhatia L.S., Curzen N.P., Calder P.C., Byrne C.D. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur. Heart J. 2012;33:1190–200. DOI: 10.1093/eurheartj/ehr453.

Treeprasertsuk S., Leverage S., Adams L.A., Lindor K.D., St. Sauver J., Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int. 2012;32:945–50. DOI: 10.1111/j.1478-3231.2011.02753.x

Blackett P.R., Sanghera D.K. Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction. J. Clin. Lipidol. 2013;7:65–81. DOI: 10.1016/j.jacl.2012.04.079.

Ballestri Stefano. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. J. Gastroenterol. 2014;20(7):1724–1745.

Cheng V.Y., Dey D., Tamarappoo B., Nakazato R., Gransar H., Miranda-Peats R. et al. Pericardial fat burden on ECG-gated noncontrast CT in asymptomatic patients who subsequently experience adverse cardiovascular events. JACC Cardiovasc. Imaging. 2010;3:352–60. DOI: 10.1016/j.jcmg.2009.12.013.

Драпкина О.М., Корнеева О.Н., Драпкина Ю.С. Эпикардиальный жир: нападающий или запасной? Рациональная фармакотерапия в кардиологии. 2013;9(3):287–291.

Drapkina O.M., Korneeva O.N., Drapkina Yu.S. Epicardial fat: a striker or a spare? Ration. Pharmacother. Cardiol. 2013;9(3):287–291. (in Russian)

Драпкина О.М., Шепель Р.Н., Деева Т.А. Толщина эпикардиального жира — «визитная карточка» метаболического синдрома. Ожирение и метаболизм. 2018;15(2):29–34. DOI: 10.14341/OMET9295.

Drapkina O.M., Shepel R.N., Deeva T.A.The thickness of the epicardial fat is the «visit card» of metabolic syndrome. Obesity and metabolism. 2018;15(2):29–34. (in Russian). DOI: 10.14341/OMET9295.

Mazurek T., Zhang L., Zalewski A. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003;108(20):2460–2466.

Gianluca Iacobellis, Giorgio Barbarini, Claudio Letizia and Giuseppe Barbaro. Epicardial Fat Thickness and Nonalcoholic Fatty Liver Disease in Obese Subjects. Obesity. 2014;22:332–336. DOI:10.1002/oby.20624.

Wolff L., Hofman A., Bos D., Krestin G.P., Vernooij M.W., Franco O.H. et al. Liver fat is related to cardiovascular risk factors and subclinical vascular disease: the Rotterdam Study. Eur. Heart J-Card. Img. 2016;17:1361–7. DOI: 10.1093/ehjci/jew174

Драпкина О.М., Корнеева О.Н. Континуум неалкогольной жировой болезни печени: от стеатоза печени до сердечно-сосудистого риска. Рациональная фармакотерапия в кардиологии. 2016;12(4):424–429. DOI: 10.20996/1819-6446-2016-12-4-424-429.

Drapkina O.M., Korneeva O.N. Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Ration. Pharmacother. Cardiol 2016;12(4):424–429. (in Russian). DOI: 10.20996/1819-6446-2016-12-4-424-429.

Fracanzani A.L., Pisano G., Consonni D., Tiraboschi S., Baragetti A., Bertelli C. et al. Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. PLoS ONE. 2016;11(9):e0162473. DOI:10.1371/journal.pone.0162473.

Verhagen S.N., Visseren F.L. Perivascular adipose tissue: as a cause of atherosclerosis. Atherosclerosis. 2011;214:3–10. DOI: 10.1016/j.atherosclerosis.2010.05.034.

Reilly S.N., Jayaram R., Nahar K., Antoniades C., Verheule S., Channon K.M. et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation. 2011;124(10):1107– 1117. DOI: 10.1161/CIRCULATIO-NAHA.111.029223.

Antoniades C., Demosthenous M., Reilly S., Margaritis M., Zhang M.H., Antonopoulos A. et al. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment. J. Am. Coll. Cardiol. 2012;59(1):60– 70. DOI: 10.1016/j.jacc.2011.08.062.

Verheule S., Tuyls E., Gharaviri A., Hulsmans S., van Hunnik A., Kuiper M. et al. Loss of continuity in the thin epicardial layer because of endomysial fibrosis increases the complexity of atrial fibrillatory conduction. Circ. Arrhythm. Electrophysiol. 2013;6:202–211. DOI: 10.1161/CIRCEP.112.975144.

Frontini A., Cinti S. Distribution and Development of Brown Adipocytes in the Murine and Human Adipose Organ. Cell Metabolism. 2010;11(4):253–6. DOI: 10.1016/j.cmet.2010.03.004.

Meijer R.I., Serne E.H., Smulders Y.M. van Hinsbergh V.W.M., Yudkin J.S., Eringa E.C. Perivascular Adipose Tissue and Its Role in Type 2 Diabetes and Cardiovascular Disease. Current Diabetes Reports. 2011;11(3):211–7. DOI: 10.1007/s11892-011-0186-y.

Lohn M., Dubrovska G., Lauterbach B., Luft F.C., Gollasch M., Sharma A.M. Periadventitial fat releases a vascular relaxing factor. FASEB J. 2002;16:1057–1063.

Verlohren S., Dubrovska G., Tsang S.Y., Essin K., Luft F.C., Huang Y. et al. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertension. 2004;44:271–276.

Gao Y., Takemori K., Su L., An W., Lu C., Sharma A. et al. Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovascular Research. 2006;71(2):363–73. DOI: 10.1016/j.cardiores.2006.03.013.

Wildman R.P., Mackey R.H., Bostom A., Thompson T., Sutton-Tyrrell K. Measures of obesity are associated with vascular stiffness in young and older adults. Hypertension. 2003;42:468–473.

Tounian P., Aggoun Y., Dubern B., Varille V., Guy-Grand B., Sidi D. et al. Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet. 2001;358:1400–1404.

Lee Y.J., Shim J.Y., Moon B.S. et al. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci.2012;57:196–203.

Kim B.J., Kim N.H., Kim B.S., Kang J.H. The association between nonalcoholic fatty liver disease, metabolic syndrome and arterial stiffness in nondiabetic, nonhypertensive individuals. Cardiology. 2012;123:54–61.

Kim H.C., Kim D.J., Huh K.B. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis. 2009;204:521–525.

Ramilli S., Pretolani S., Muscari A. et al. Carotid lesions in outpatients with non-alcoholic fatty liver disease. World J Gastroentero.l 2009;15(38):4770–4.

Eklioglu B.S., Atabek M.E., Akyürek N., Alp H. Assessment of Cardiovascular Parameters in Obese Children and Adolescents with Non-Alcoholic Fatty Liver Disease. J. Clin. Res. Pediatr. Endocri-nol. 2015;7:222–227.

Musso G., Gambino R., Tabibian J.H., Ekstedt M., Kechagias S., Hamaguchi M. et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001680.

Christopher D. Byrne, Giovanni Targher. NAFLD as a driver of chronic kidney disease. Journal of Hepatology. 2020;72:785–801.

Chughtai H.L., Morgan T.M., Rocco M., Stacey B., Brinkley T.E., Ding J. et al. Renal sinus fat and poor blood pressure control in mid-dle-aged and elderly individuals at risk for cardiovascular events. Hypertension. 2010;56:901–906.

Wagner R., Machann J., Lehmann R., Rittig K., Schick F., Lenhart J. et al. Exercise-induced albuminuria is associated with perivascular renal sinus fat in individuals at increased risk of type 2 diabetes. Dia-betologia. 2012;55:2054–2058.

Foster M.C., Hwang S.J., Porter S.A., Massaro J.M., Hoffmann U., Fox C.S. Fatty kidney, hypertension, and chronic kidney disease: the framingham heart study. Hypertension. 2011;58:784–790

Lamacchia O., Nicastro V., Camarchio D., Valente U., Grisorio R., Gesualdo L. et al. Para-and perirenal fat thickness is an independent predictor of chronic kidney disease, increased renal resistance index and hyperuricaemia in type-2 diabetic patients. Nephrol. Dial. Trans-plant. 2011;26:892–898.

Dwyer T.M., Bigler S.A., Moore N.A., Carroll J.F., Hall J.E. The altered structure of renal papillary outflow tracts in obesity. Ultra-struct. Pathol. 2000;24:251–257.

Alexopoulos N., Katritsis D., Raggi P. Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis. Atheroscle-rosis. 2014;233:104–112.

Engin A. The pathogenesis of obesity-associated adipose tissue in-flammation. Adv Exp. Med. Biol. 2017;960:221–245.

Stolarczyk E. Adipose tissue inflammation in obesity: a metabolic or immune response? Curr. Opin. Pharmacol. 2017;37:35–40.

Reilly S.M., Saltiel A.R. Adapting to obesity with adipose tissue inflammation. Nat. Rev. Endocrinol. 2017;13:633–643.

Rosso C., Kazankov K., Younes R., Esmaili S., Marietti M., Sac-co M. et al. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. J. Hepatol. 2019;71(5):1012–1021.

Soelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169–2180.

Pawlak M., Lefebvre P., Staels B. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibro-sis in non-alcoholic fatty liver disease. J. Hepatol. 2015;62:720–733.

Cai D., Yuan M., Frantz D.F., Melendez P.A., Hansen L., Lee J. et al. Local and systemic insulin resistance resulting from hepatic ac-tivation of IKK-beta and NF-kappaB. Nat. Med. 2005;11:183–190.

Siragy H.M., Carey R.M. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am. J. Nephrol. 2010;31:541–550.

Тargher G., Byrne C.D. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat. Rev. Nephrol. 2017;13:297–310.

Ix J.H., Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J. Am. Soc. Nephrol. 2010;21:406–412.

Onnerhag K., Dreja K., Nilsson P.M., Lindgren S. Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities. Clin. Res. Hepatol. Gastroenterol. 2019;43(5):542–550.

Yilmaz Y., Alahdab Y.O., Yonal O., Kurt R., Kedrah A.E., Celikel C.A. et al. Microalbuminuria in nondiabetic patients with non-alcoholic fatty liver disease: association with liver fibrosis. Metabolism. 2010;59:1327–1330.

Targher G., Bertolini L., Rodella S., Lippi G., Zoppini G., Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin. J. Am. Soc. Nephrol. 2010;5:2166–2171.

Pan L.L., Zhang H.J., Huang Z.F., Sun Q., Chen Z., Li Z.B. et al. Intrahepatic triglyceride content is independently associated with chronic kidney disease in obese adults: a cross-sectional study. Metabolism. 2015;64:1077–1085.

Pacifico L., Bonci E., Andreoli G.M., Di Martino M., Gallozzi A., De Luca E. et al. The impact of non-alcoholic fatty liver disease on renal function in children with overweight/obesity. Int. J. Mol. Sci. 2016;17:E1218.

Kang H.R., Kang D., Sinn D.H., Gu S., Cho S.J., Lee J.E. et al. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Sci. Rep. 2018;8:4718.

Wilechansky R.M., Pedley A., Massaro J.M., Hoffmann U., Benjamin E.J., Long M.T. Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham heart study: a secondary analysis. Liver Int. 2019;39:1535–1544.

Targher G., Chonchol M., Bertolini L., Rodella S., Zenari L., Lippi G. et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J. Am. Soc. Nephrol. 2008;19:1564–1570.

Mantovani A., Zaza G., Byrne C.D., Lonardo A., Zoppini G., Bonora E. et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism. 2018;79:64–76.

Targher G., Byrne C.D., Lonardo A., Zoppini G., Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J. Hepatol. 2016;65:589–600.

The authors declare that there are no conflicts of interest present.